ERK1/2 regulates SIRT2 deacetylase activity

Biochemical and Biophysical Research Communications

Volumn 437, Issue 2, 2013, Pages 245-249

  Choi, You Hee ^a   Kim, Hangun ^b   Lee, Sung Ho ^a   Jin, Yun Hye ^a   Lee, Kwang Youl ^a  

^a Chonnam National University   (South Korea)

^b Sunchon National University   (South Korea)

Author keywords

Deacetylation; ERK1 2; Protein level; SIRT2; Stability

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; HISTONE DEACETYLASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SIRTUIN 2;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION;

DEACETYLATION; ERK1/2; PROTEIN LEVEL; SIRT2; STABILITY;

ENZYME ACTIVATION; ENZYME STABILITY; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; SIRTUIN 2;

MAMMALIA;

EID: 84880746649     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.053     Document Type: Article

References (26)

1. Blander G., Guarente L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 2004, 73:417-435.
2. Hernick M., Fierke C.A. Zinc hydrolases: the mechanisms of zinc-dependent deacetylases. Arch. Biochem. Biophys. 2005, 433:71-84.
3. Marmorstein R. Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases. Biochem. Soc. Trans. 2004, 32:904-909.
4. Vaquero A., Scher M., Lee D., Erdjument-Bromage H., Tempst P., Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 2004, 16:93-105.
5. Afshar G., Murnane J.P. Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2. Gene 1999, 234:161-168.
6. North B.J., Marshall B.L., Borra M.T., Denu J.M., Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 2003, 11:437-444.
7. Southwood C.M., Peppi M., Dryden S., Tainsky M.A., Gow A. Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem. Res. 2007, 32:187-195.
8. Zuo Q., Wu W., Li X., Zhao L., Chen W. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncol. Rep. 2012, 27:819-824.
9. Nahhas F., Dryden S.C., Abrams J., Tainsky M.A. Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin. Mol. Cell. Biochem. 2007, 303:221-230.
10. Wang F., Chan C.H., Chen K., Guan X., Lin H.K., Tong Q. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene 2012, 31:1546-1557.
11. Jing E., Gesta S., Kahn C.R. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab. 2007, 6:105-114.
12. Rothgiesser K.M., Erener S., Waibel S., Luscher B., Hottiger M.O. SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J. Cell Sci. 2010, 123:4251-4258.
13. Harting K., Knoll B. SIRT2-mediated protein deacetylation: an emerging key regulator in brain physiology and pathology. Eur. J. Cell Biol. 2010, 89:262-269.
14. Todorovic V., Desai B.V., Patterson M.J., Amargo E.V., Dubash A.D., Yin T., Jones J.C., Green K.J. Plakoglobin regulates cell motility through Rho- and fibronectin-dependent Src signaling. J. Cell Sci. 2010, 123:3576-3586.
15. Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y. Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem. Biophys. Res. Commun. 2008, 368:690-695.
16. Han Y., Jin Y.H., Kim Y.J., Kang B.Y., Choi H.J., Kim D.W., Yeo C.Y., Lee K.Y. Acetylation of Sirt2 by p300 attenuates its deacetylase activity. Biochem. Biophys. Res. Commun. 2008, 375:576-580.
17. Li Y., Matsumori H., Nakayama Y., Osaki M., Kojima H., Kurimasa A., Ito H., Mori S., Katoh M., Oshimura M., Inoue T. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells 2011, 16:34-45.
18. Peck B., Chen C.Y., Ho K.K., Di Fruscia P., Myatt S.S., Coombes R.C., Fuchter M.J., Hsiao C.D., Lam E.W. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol. Cancer Ther. 2010, 9:844-855.
19. Jang S.Y., Kim S.Y., Bae Y.S. P53 deacetylation by SIRT1 decreases during protein kinase CKII downregulation-mediated cellular senescence. FEBS Lett. 2011, 585:3360-3366.
20. Ji Z., Njauw C.N., Taylor M., Neel V., Flaherty K.T., Tsao H. P53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J. Invest. Dermatol. 2012, 132:356-364.
21. Kojima K., Konopleva M., Samudio I.J., Ruvolo V., Andreeff M. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res. 2007, 67:3210-3219.
22. Shin J., Zhang D., Chen D. Reversible acetylation of metabolic enzymes celebration: SIRT2 and p300 join the party. Mol. Cell 2011, 43:3-5.
23. Alcain F.J., Villalba J.M. Sirtuin inhibitors. Expert Opin. Ther. Pat. 2009, 19:283-294.
24. Fraga M.F., Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet. 2007, 23:413-418.
25. Lim C.S. Human SIRT1: a potential biomarker for tumorigenesis?. Cell Biol. Int. 2007, 31:636-637.
26. Matsushita N., Takami Y., Kimura M., Tachiiri S., Ishiai M., Nakayama T., Takata M. Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells 2005, 10:321-332.